Further, no differences in the ratio of CD19+CD138+ / CD19+CD138- lymphocyte populations between patients with CIS, RRMS, SPMS, PPMS and OND could be found (S1 Fig in Supplementary Tables and Figures). The gene discussed is CD19; the disease is in situ carcinoma.